# Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer

> **NCT00548899** · PHASE2 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 36 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Nexavar (Sorafenib)

## Key facts

- **NCT ID:** NCT00548899
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2011-09
- **Final completion:** 2011-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2015-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548899, "Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00548899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*